Company intelligence / Profile preview

Lutroo Imaging

United States

Ownership: Private
Development stage: Other

Overview

Lutroo Imaging has completed preclinical proof-of-concept studies demonstrating that its PET radiotracer, Radiocaine, can objectively localize and measure pain in vivo; Phase 1 trial is launching Q2 2025, supported by NIH HEAL Initiative funding

Therapeutic areas: Neurology
Modalities: RadiopharmaceuticalDevice
Industry: Medical Imaging

Partnerships

NIH HEAL Initiative (grant/funding)MassChallenge Switzerland (accelerator finalist)

Beyond the preview

Go deeper on Lutroo Imaging.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lutroo Imaging.

Explore the full profile